DE1642662A1 - Verfahren zur Gewinnung von Urokinase - Google Patents
Verfahren zur Gewinnung von UrokinaseInfo
- Publication number
- DE1642662A1 DE1642662A1 DE19651642662 DE1642662A DE1642662A1 DE 1642662 A1 DE1642662 A1 DE 1642662A1 DE 19651642662 DE19651642662 DE 19651642662 DE 1642662 A DE1642662 A DE 1642662A DE 1642662 A1 DE1642662 A1 DE 1642662A1
- Authority
- DE
- Germany
- Prior art keywords
- urokinase
- solution
- urine
- activity
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005356 urokinase Drugs 0.000 title claims description 165
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title claims description 164
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims description 164
- 238000000034 method Methods 0.000 title claims description 70
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000000243 solution Substances 0.000 claims description 82
- 239000002244 precipitate Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000001698 pyrogenic effect Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 210000002700 urine Anatomy 0.000 description 50
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 38
- 239000001768 carboxy methyl cellulose Substances 0.000 description 38
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 38
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 38
- 239000000725 suspension Substances 0.000 description 37
- 239000000499 gel Substances 0.000 description 25
- 239000007788 liquid Substances 0.000 description 23
- 238000003756 stirring Methods 0.000 description 20
- 238000005119 centrifugation Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 238000010828 elution Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 239000011575 calcium Substances 0.000 description 13
- 239000011521 glass Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 229910019142 PO4 Inorganic materials 0.000 description 11
- 235000021317 phosphate Nutrition 0.000 description 11
- 239000002510 pyrogen Substances 0.000 description 11
- 239000001488 sodium phosphate Substances 0.000 description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 description 11
- 238000001179 sorption measurement Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- 239000000440 bentonite Substances 0.000 description 9
- 229910000278 bentonite Inorganic materials 0.000 description 9
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- -1 aluminum silicate compound Chemical class 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000000540 fraction c Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000007669 thermal treatment Methods 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000002196 fr. b Anatomy 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000015107 ale Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- SWTDCJKWVSTIGV-UHFFFAOYSA-N 2-ethoxyacridine Chemical compound C1=CC=CC2=CC3=CC(OCC)=CC=C3N=C21 SWTDCJKWVSTIGV-UHFFFAOYSA-N 0.000 description 1
- HXMVNCMPQGPRLN-UHFFFAOYSA-N 2-hydroxyputrescine Chemical compound NCCC(O)CN HXMVNCMPQGPRLN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000711981 Sais Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001178520 Stomatepia mongo Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US404156A US3355361A (en) | 1964-10-15 | 1964-10-15 | Recovery and purification of urokinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1642662A1 true DE1642662A1 (de) | 1971-05-19 |
Family
ID=23598395
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19651642662 Pending DE1642662A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651442162 Pending DE1442162A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642660 Pending DE1642660A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642661 Pending DE1642661A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19651442162 Pending DE1442162A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642660 Pending DE1642660A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642661 Pending DE1642661A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3355361A (https=) |
| JP (3) | JPS5142195B1 (https=) |
| AT (1) | AT278239B (https=) |
| CH (1) | CH495384A (https=) |
| DE (4) | DE1642662A1 (https=) |
| DK (4) | DK117821B (https=) |
| GB (1) | GB1068817A (https=) |
| SE (1) | SE314045B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH467075A (de) * | 1964-07-01 | 1969-01-15 | Pharmexbio S A | Verfahren zur Gewinnung von Urokinase |
| US3477910A (en) * | 1966-10-17 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3542646A (en) * | 1966-11-22 | 1970-11-24 | Green Cross Corp | Process for fractionally obtaining urokinase and blood coagulation accelerator in human urine |
| US3477913A (en) * | 1967-10-31 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3544427A (en) * | 1968-04-18 | 1970-12-01 | Century Lab Inc | Method of production of urokinase |
| US3620924A (en) * | 1969-04-01 | 1971-11-16 | Baxter Laboratories Inc | Production of acid-active lactase |
| FR2190412A1 (en) * | 1972-06-30 | 1974-02-01 | Choay Sa | Stable,pyrogen-free urokinase prepns - from human urine |
| BE789189A (fr) * | 1971-09-24 | 1973-03-22 | Choay Sa | Perfectionnements aux procedes de preparation, de depyrogenation et de stabilisation de l'urokinase et compositions obtenues |
| JPS5341485A (en) * | 1976-09-25 | 1978-04-14 | Wakamoto Pharma Co Ltd | Removing method of pyrogenic substance containe in urokinase |
| US4066506A (en) * | 1976-10-08 | 1978-01-03 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Method of separating and purifying two active forms of urokinase using affinity chromatography |
| JPS53142592A (en) * | 1977-05-13 | 1978-12-12 | Green Cross Corp:The | Stabilization of urokinase heating |
| JPS53142593A (en) * | 1977-12-12 | 1978-12-12 | Green Cross Corp:The | Stabilization of urokinase by heating |
| JPS54155784U (https=) * | 1978-04-21 | 1979-10-30 | ||
| EP0040238B1 (en) * | 1979-11-13 | 1984-07-11 | HUSAIN, Syed Shaukat | Plasminogen activators useful as therapeutic and diagnostic agents and their isolation |
| USRE32271E (en) * | 1979-11-13 | 1986-10-28 | Isolation of plasminogen activators useful as therapeutic and diagnostic agents | |
| US4558010A (en) * | 1980-04-03 | 1985-12-10 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom |
| US4370417A (en) * | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
| JPS58189122A (ja) * | 1982-04-30 | 1983-11-04 | Kaken Pharmaceut Co Ltd | 高脂血症予防治療剤 |
| DE3439980A1 (de) * | 1984-11-02 | 1986-05-07 | Behringwerke Ag, 3550 Marburg | Verfahren zur reinigung sowie pasteurisierung von urokinase |
| US4920051A (en) * | 1988-02-03 | 1990-04-24 | Damon Biotech, Inc. | Recovery of urokinase compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3281331A (en) * | 1961-11-08 | 1966-10-25 | Astra Ab | Process of isolating and separating proteolytic enzymes |
-
1964
- 1964-10-15 US US404156A patent/US3355361A/en not_active Expired - Lifetime
-
1965
- 1965-10-05 GB GB42311/65A patent/GB1068817A/en not_active Expired
- 1965-10-11 CH CH1400465A patent/CH495384A/de not_active IP Right Cessation
- 1965-10-12 AT AT921765A patent/AT278239B/de not_active IP Right Cessation
- 1965-10-13 DE DE19651642662 patent/DE1642662A1/de active Pending
- 1965-10-13 DE DE19651442162 patent/DE1442162A1/de active Pending
- 1965-10-13 DE DE19651642660 patent/DE1642660A1/de active Pending
- 1965-10-13 DE DE19651642661 patent/DE1642661A1/de active Pending
- 1965-10-14 DK DK527265AA patent/DK117821B/da unknown
- 1965-10-15 JP JP40062990A patent/JPS5142195B1/ja active Pending
- 1965-10-15 SE SE13409/65A patent/SE314045B/xx unknown
-
1967
- 1967-02-13 DK DK77567AA patent/DK115536B/da unknown
- 1967-02-13 DK DK77467AA patent/DK112162B/da unknown
- 1967-02-13 DK DK77667AA patent/DK112232B/da unknown
-
1976
- 1976-05-14 JP JP5521276A patent/JPS5619229B1/ja active Pending
- 1976-05-14 JP JP5521176A patent/JPS5619228B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5142195B1 (https=) | 1976-11-13 |
| US3355361A (en) | 1967-11-28 |
| AT278239B (de) | 1970-01-26 |
| DK117821B (da) | 1970-06-08 |
| DE1442162A1 (de) | 1969-01-16 |
| DK112232B (da) | 1968-11-25 |
| SE314045B (https=) | 1969-09-01 |
| DE1642661A1 (de) | 1971-07-29 |
| GB1068817A (en) | 1967-05-17 |
| JPS5619228B1 (https=) | 1981-05-06 |
| DE1642660A1 (de) | 1971-07-29 |
| DK112162B (da) | 1968-11-18 |
| DK115536B (da) | 1969-10-20 |
| JPS5619229B1 (https=) | 1981-05-06 |
| CH495384A (de) | 1970-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1642662A1 (de) | Verfahren zur Gewinnung von Urokinase | |
| DE69033626T2 (de) | Mittel zur Hemmung des Komplementsystems hergestellt aus Fucanen aus braunen Algen | |
| Swim et al. | Effect of Pluronic F68 on growth of fibroblasts in suspension on rotary shaker | |
| Woodin | Purification of the two components of leucocidin from Staphylococcus aureus | |
| DE69229272T2 (de) | Topischer fibrinogenkomplex | |
| DE2535554C2 (de) | Biologisches Verfahren | |
| US4083961A (en) | Plasminogen activator pharmaceutical compositions | |
| CH644520A5 (de) | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors. | |
| DE69826531T2 (de) | Verfahren und vorrichtung zur herstellung von gereinigten plasmaproteinen | |
| DE2752694A1 (de) | Verfahren zur gewinnung von immunglobulin zur intravenoesen verabreichung | |
| DE1814028A1 (de) | Verfahren zur Bestimmung des Hydroxyprolingehaltes von biologischen Fluessigkeiten und diagnostische Packung fuer diese Bestimmung | |
| DE4333805C2 (de) | Verfahren zur Extraktion von Nucleinsäuren und Verfahren zum Nachweis spezifizierter Nucleinsäuresequenzen | |
| EP1789445B1 (de) | Verfahren zur entfernung von fibronektin aus plasmafraktionen | |
| DE2306107A1 (de) | Verfahren zur entfernung von hepatitisantigen aus einer proteinfraktion | |
| DE2456589C2 (de) | Verfahren zur Herstellung eines Plasminogen-Aktivators und denselben enthaltendes Mittel | |
| EP3662080A1 (de) | Verfahren und zusammensetzung zur stabilisierung zellfreier nukleinsäuren und zellen | |
| DE1442134C3 (de) | In vivo antikoagulierend wirkendes und defibrinierendes Enzym | |
| DE68912270T2 (de) | Lyophilisiertes MDM enthaltende Zusammensetzung und Verfahren zu deren Herstellung. | |
| EP0035726B1 (de) | Verfahren und diagnostisches Mittel zur direkten Bestimmung des Lipidgehaltes der beta-Lipoproteine des Blutes | |
| DE2353318A1 (de) | Verbessertes verfahren zur herstellung von plasminogen-aktivator | |
| DE2428955C3 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
| EP0281089B1 (de) | Verfahren zur Herstellung von Faktor VIII:C-Mangelplasma und ein so erhaltenes Mangelplasma | |
| Butler et al. | Proliferative activity in the proximal and distal colon of the rat after fasting and refeeding | |
| CH660634A5 (de) | Verfahren zur herstellung von natuerlichem immunoadsorbens. | |
| DE1949314A1 (de) | Prothrombinkomplex und Verfahren zu dessen Herstellung |